NASDAQ: RZLT - Rezolute, Inc.

Yield per half year: +17.81%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Rezolute, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc.

more details
and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2014-05-01
ISIN US76200L3096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.rezolutebio.com
Цена ао 2.12
Change price per day: -0.998% (5.01)
Change price per week: +12.98% (4.39)
Change price per month: -0.6012% (4.99)
Change price per 3 month: -0.4016% (4.98)
Change price per half year: +17.81% (4.21)
Change price per year: +399.5% (0.993)
Change price per 3 year: +10.22% (4.5)
Change price per 5 year: +4 810.89% (0.101)
Change price per 10 year: 0% (4.96)
Change price per year to date: -8.82% (5.44)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.65 8
P/E 0 0
EV/EBITDA -1.91 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -53.39 0
ROE, % -57.73 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0326 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 237.06 10
Yield EPS, % -61.99 0
Total: 6
More

Institutions Volume Share, %
Federated Hermes, Inc. 10154327 0
Vivo Capital, LLC 3242842 38.52
Nantahala Capital Management, LLC 3075414 36.53
Stonepine Capital Management, LLC 2768656 32.89
First Manhattan Company 2680978 31.85
Blackstone Inc 1537684 18.27
Vanguard Group Inc 1407652 16.72
Caxton Corporation 1318967 15.67
Sphera Funds Management Ltd. 996710 11.84
Adage Capital Partners GP L.L.C. 631690 7.5

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.05811 17.09 1.54048
Avantis U.S Small Cap Equity ETF 0.01284 27.77 1.68271
Dimensional U.S. Targeted Value ETF 0.00052 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0.0002 30.76 1.47098



Head Job title Payment Year of birth
Mr. Nevan Charles Elam J.D. Founder, CEO & Acting Chairman of the Board 973.65k 1967 (58 years)
Dr. Brian Kenneth Roberts M.D. Chief Medical Officer 738.86k 1975 (50 years)
Dr. Davelyn Eaves Hood M.B.A., M.D. Director and Head of Scientific & Patient Affairs N/A
Mr. Michael R. Deperro Senior VP & Head of Corporate Development N/A
Mr. Michael Covarrubias Senior VP & Head of Program & Portfolio Management N/A
Mr. Chris Milks VP & Head of Finance N/A
Dr. Raj Agrawal M.D. VP & Head of Ophthalmological Clinical Development N/A
Ms. Robyn Sweinhart VP & Head of Quality N/A
Mr. Daron G. Evans M.B.A., M.S. Chief Financial Officer N/A 1974 (51 year)
Ms. Erin O'Boyle Senior VP & Head of Clinical Operations

Address: United States, Redwood City. CA, 201 Redwood Shores Parkway - open in Google maps, open in Yandex maps
Website: https://www.rezolutebio.com